Home » Newsletters » BioWorld Science

BioWorld Science

May 6, 2020

View Archived Issues

Where exercise-induced IL-6 comes and goes

How does innate immunity remember? Not via polycomb

Vir and Alnylam identify development candidate targeting the SARS-CoV-2 genome

Model created for multiple system atrophy-C and primary progressive multiple sclerosis

Positive topline results from global phase III INNO2VATE program of vadadustat

First patients enrolled in pivotal MACOVIA study of MultiStem in COVID-19-induced ARDS

Innovation announces new agreement to study inhibitory effects of brilacidin on SARS-CoV-2

Phase I results of bivalent CD19/CD22 CAR T cells in patients with ALL

Rafael Pharmaceuticals and Roswell Park Comprehensive Cancer Center to evaluate CPI-613

Unigen divulges tyrosinase and melanin inhibitors

Nanjing Sanhome Pharmaceutical synthesizes TGFBR1 inhibitors

Low-dose sorafenib shown to ameliorate NASH

Servier and Vernalis describe USP7 inhibitors

Medshine Discovery identifies TLR8 agonists for HBV infection

Heptares Therapeutics presents new histamine H4 receptor antagonists

Positive topline data from the UNITY-CLL phase III study

ORIC Pharmaceuticals' OP-5244 reverses immunosuppression in vivo

Veru reports positive phase Ib data for VERU-111

Novel animal model of cardiac reperfusion injury

FDA clears Kiadis to begin phase II study of K-NK-002 produced with PM21

Enrollment on track in phase IIb GALACTIC-1 study of GB-0139 in IPF

Genzyme initiates phase III study of venglustat in late-onset GM2 gangliosidosis

ProMIS identifies novel antagonists against RACK1 for neurodegenerative diseases

Health Canada clears initiation of phase II study of LAU-7b for COVID-19

FDA approves Farxiga for HFrEF